Mineralys Therapeutics Inc MLYS

Stock XNAS Rating as of Nov 6, 2026

News

Mineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026
GlobeNewswire Nov 8, 2026, 9:35:00 PM
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Nov 6, 2026, 1:00:00 PM
Mineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
GlobeNewswire Nov 4, 2026, 9:05:00 PM
Mineralys Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire Nov 3, 2026, 9:05:00 PM
Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026
GlobeNewswire Oct 28, 2026, 8:05:00 PM
Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International
GlobeNewswire Oct 28, 2026, 11:05:00 AM
Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026
GlobeNewswire Oct 22, 2026, 10:40:00 PM
Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats
GlobeNewswire Oct 19, 2026, 8:05:00 PM
Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026
GlobeNewswire Oct 9, 2026, 1:00:00 PM
Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026
GlobeNewswire Oct 2, 2026, 8:30:00 PM
Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026
GlobeNewswire Oct 1, 2026, 8:05:00 PM
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Sep 29, 2026, 8:05:00 PM
Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
GlobeNewswire Sep 24, 2026, 8:05:00 PM
Mineralys Therapeutics’ Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026
GlobeNewswire Sep 23, 2026, 8:05:00 PM
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Sep 21, 2026, 8:05:00 PM
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Sep 9, 2026, 8:05:00 PM
Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
GlobeNewswire Aug 26, 2026, 12:00:00 PM
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Aug 13, 2026, 8:05:00 PM
Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
GlobeNewswire Aug 11, 2026, 8:05:00 PM
Mineralys Therapeutics' Treatment Fails to Reduce Sleep Apnea
Global News Select Mar 9, 2026, 11:29:00 PM

Mineralys Therapeutics Inc MLYS

News

Mineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Mineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Mineralys Therapeutics to Participate in Upcoming Investor Conferences

Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026

Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International

Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026

Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats

Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026

Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026

Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum

Mineralys Therapeutics’ Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference

Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Mineralys Therapeutics' Treatment Fails to Reduce Sleep Apnea

Sponsor Center

What We Do

Company

Get Help